AN2 Therapeutics, Inc. 8-K

What Happened
AN2 Therapeutics (ANTX) filed an 8-K reporting that on January 26, 2026 the Board appointed Sarah Williams as Vice President, Controller and Principal Accounting Officer effective February 1, 2026. Ms. Williams, age 38, has been AN2’s Corporate Controller since May 2024 and previously held accounting roles at Gritstone Bio, Bio‑Rad, BDO and Crowe. In connection with the transition, the company executed an Amended and Restated Employment Letter Agreement with CFO Lucy Day dated January 29, 2026 to revise her compensation and roles; Ms. Day will remain Chief Financial Officer and Principal Financial Officer.

Key Details

• Sarah Williams: promoted to VP, Controller & Principal Accounting Officer effective Feb 1, 2026; will receive an annual base salary of $310,000 and a target annual bonus of 30% of base salary. She will enter the company’s standard indemnity agreement and be eligible under the Officer Severance Plan.
• Lucy Day: employment amendment effective Jan 29, 2026 — immediate through Mar 31, 2026 annual base salary $335,400; beginning Apr 1, 2026 annual base salary reduced to $223,600. If involuntarily terminated (not in connection with a change in control) on or after Apr 1, 2026, Ms. Day would be eligible for 50% of the severance benefits under the Officer Severance Plan. Outstanding equity awards will continue to vest while she provides services.
• No related-person transactions or special arrangements were disclosed regarding Ms. Williams’ selection; Ms. Williams is an inactive CPA and holds a B.S. in Business (Accounting).

Why It Matters
This filing documents a leadership change in AN2’s accounting function and a negotiated pay reduction for the CFO as part of a cost-management transition. Investors should note continuity in finance leadership (CFO remains in place) while the company shifts the Principal Accounting Officer role to Ms. Williams, and that the amended CFO terms reduce ongoing cash compensation after April 1, 2026 and limit severance exposure to 50% of plan benefits for involuntary termination. These are operational and governance updates that can affect corporate expense run-rate and financial reporting responsibilities.